Correlation Between Keros Therapeutics and Acrivon Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Keros Therapeutics and Acrivon Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Keros Therapeutics and Acrivon Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Keros Therapeutics and Acrivon Therapeutics, Common, you can compare the effects of market volatilities on Keros Therapeutics and Acrivon Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Keros Therapeutics with a short position of Acrivon Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Keros Therapeutics and Acrivon Therapeutics,.

Diversification Opportunities for Keros Therapeutics and Acrivon Therapeutics,

0.74

Correlation Coefficient

Keros Therapeutics  Acrivon Therapeutics,

Poor diversification

The 3 months correlation between Keros and Acrivon is 0.74. Overlapping area represents the amount of risk that can be diversified away by holding Keros Therapeutics and Acrivon Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Acrivon Therapeutics, and Keros Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Keros Therapeutics are associated (or correlated) with Acrivon Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Acrivon Therapeutics, has no effect on the direction of Keros Therapeutics i.e., Keros Therapeutics and Acrivon Therapeutics, go up and down completely randomly.

Pair Corralation between Keros Therapeutics and Acrivon Therapeutics,

Given the investment horizon of 90 days Keros Therapeutics is expected to under-perform the Acrivon Therapeutics,. In addition to that, Keros Therapeutics is 2.3 times more volatile than Acrivon Therapeutics, Common. It trades about -0.19 of its total potential returns per unit of risk. Acrivon Therapeutics, Common is currently generating about -0.02 per unit of volatility. If you would invest  644.00  in Acrivon Therapeutics, Common on October 22, 2024 and sell it today you would lose (66.00) from holding Acrivon Therapeutics, Common or give up 10.25% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Keros Therapeutics  vs.  Acrivon Therapeutics, Common

Keros Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Keros Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in February 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Acrivon Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in February 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Pair Trading with Keros Therapeutics and Acrivon Therapeutics,

The main advantage of trading using opposite Keros Therapeutics and Acrivon Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Keros Therapeutics position performs unexpectedly, Acrivon Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acrivon Therapeutics, will offset losses from the drop in Acrivon Therapeutics,'s long position.

The idea behind Keros Therapeutics and Acrivon Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.